Quick answer
Several genuinely approved peptide medicines act on the gut — teduglutide for short bowel syndrome, linaclotide and plecanatide for constipation disorders. The popular ones marketed for general "gut healing", chiefly BPC-157, have animal evidence only and no completed human trials.
Peptides and the gut barrier
A lot of gut-peptide interest centers on the intestinal barrier — the lining that controls what passes from the gut into the body. When that barrier is disrupted (sometimes called "leaky gut"), it's linked to inflammatory and autoimmune conditions.[2] Several peptides are studied for protecting or restoring this barrier and calming gut inflammation.
Which peptides are studied for the gut
| Peptide | Gut angle | Status |
|---|---|---|
| Teduglutide | Regrows intestinal lining in short bowel syndrome | FDA-approved |
| Linaclotide / plecanatide | IBS-C and chronic constipation | FDA-approved |
| Larazotide | Tightens the gut barrier (studied in celiac disease) | Investigational[1] |
| BPC-157 | Gut/tissue healing — its original research focus | Research chemical (animal data) |
| KPV | Anti-inflammatory in the gut | Research chemical |
| VIP | Gut signaling & anti-inflammation | Endogenous / investigational |
The spread is instructive: the approved gut peptides treat specific diagnosed conditions, while the popular "gut healing" ones (BPC-157, KPV) rest on animal data.
BPC-157 and the gut
BPC-157 is the peptide most marketed for gut health, and notably its original research was about the gastrointestinal tract — it derives from a protective protein found in gastric juice, and rodent studies show protection and healing of stomach and intestinal lesions. But this remains animal evidence: there are no completed human trials, and it's an unapproved research chemical. Promising origin story, unproven in people.
"Leaky gut": what is established and what isn't
Most peptide marketing aimed at gut health invokes leaky gut, so it is worth separating the science from the slogan.
What is established: intestinal permeability is a real, measurable physiological property. The gut lining is a single layer of cells held together by tight junctions that regulate what crosses from the gut into the bloodstream. Permeability genuinely increases in a number of recognized conditions, including coeliac disease, inflammatory bowel disease, and critical illness, and the protein zonulin is a documented regulator of those junctions. None of this is fringe science.
What is not established: "leaky gut syndrome" as a standalone diagnosis causing a broad range of unrelated symptoms — fatigue, brain fog, joint pain, skin problems — is not a recognized clinical entity. The unresolved question is one of direction: increased permeability is well documented as a feature of certain diseases, but whether it causes them, or results from them, is largely unsettled.
That distinction matters commercially, because the leap from "permeability is real" to "therefore this peptide will fix your symptoms" skips the entire causal question and every step of clinical testing. Larazotide, which targets tight junctions directly, has been studied in coeliac disease specifically — a defined condition with a defined mechanism — not as a general gut-repair agent.
Approved gut peptide drugs versus research peptides
The gut is one area where genuinely approved peptide medicines exist, which makes the contrast with research chemicals unusually clear.
Approved peptide medicines acting on the gut include:
- Linaclotide and plecanatide, approved for chronic idiopathic constipation and IBS with constipation. They act on guanylate cyclase-C receptors in the intestinal lining to increase fluid secretion and transit.
- Teduglutide, a GLP-2 analog approved for short bowel syndrome, where it promotes intestinal absorption and reduces dependence on parenteral nutrition.
- Octreotide, used for severe secretory diarrhoea and certain hormone-secreting tumours.
Each was tested in randomized trials in defined patient populations, reviewed by regulators, and carries labeled indications and known side effects.
On the other side sit BPC-157 and similar compounds, promoted for general gut healing on the strength of rodent studies, with no completed human trials. The gap between the two groups is not a matter of one being newer — it is the difference between demonstrated effect in people and inference from animals.
It is also worth noting that persistent digestive symptoms warrant a diagnosis. Conditions like coeliac disease, inflammatory bowel disease, and infections are treatable, and self-treating an undiagnosed gut problem with an unapproved compound mainly delays finding out what is actually wrong.
The honest bottom line
If you have a diagnosed gut condition, the relevant peptides may be approved medicines (teduglutide, linaclotide, plecanatide) prescribed by a doctor — real, proven options. The "gut healing" research peptides sold online are a different tier: biologically interesting, unproven in humans, and unregulated. See are peptides safe? and how peptide research is graded.
Frequently asked questions
What peptides are good for gut health?
It depends on the goal. FDA-approved gut peptides include teduglutide (short bowel syndrome) and linaclotide/plecanatide (IBS-C and constipation). Larazotide is investigational for the gut barrier. BPC-157 and KPV are popular for 'gut healing' but rest on animal data and are unapproved.
Does BPC-157 heal the gut?
BPC-157's original research focused on the gastrointestinal tract, and rodent studies show it protects and heals stomach and intestinal lesions. However, there are no completed human trials, so its effect on the human gut is unproven, and it is an unapproved research chemical.
Are there peptides for leaky gut?
Larazotide is the peptide most associated with the intestinal barrier ('leaky gut'), studied to tighten the gut lining in conditions like celiac disease, but it remains investigational and not approved. 'Leaky gut' itself is a still-developing area of research.
Which gut peptides are FDA-approved?
Teduglutide (Gattex) for short bowel syndrome, and linaclotide (Linzess) and plecanatide (Trulance) for IBS with constipation and chronic constipation, are FDA-approved gut peptides. BPC-157, KPV, and larazotide are not approved.
Further reading
Selected peer-reviewed sources on this topic, labelled by type. A citation is a reference, not an endorsement.
- Tajik N, Frech M, Schulz O, et al. Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis. Nat Commun. 2020. Peer-reviewed study
- Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 2009. Peer-reviewed study